1,500-year-old bucket with human bones found inside was cremation burial vessel, archaeologists say
A 1,500-year-old bucket discovered in England has been identified as an ancient cremation burial vessel, experts said.
The 6th-century bucket was found at Sutton Hoo, an archaeological site near Suffolk, England, that is home to two ancient cemeteries. Fragments of the bucket, named the Bromeswell bucket, were first found in 1986. Researchers found more pieces of the relic last year during an excavation by Time Team, a British TV show where archaeologists conduct excavations on-camera.
An analysis of the newly-discovered pieces determined that Time Team had found the entire base of the bucket, and that it contained human bone fragments, the National Trust, a U.K.-based conservation organization, said in a news release. The bones included part of an ankle bone and fragments of a skull, which the National Trust said was proof of an "early Anglo-Saxon cremation burial."
Some of the pieces of the Bromeswell Bucket on display.
David Brunetti, National Trust Images
Angus Wainwright, a National Trust archaeologist, said in the news release that the burial appeared to be "very special," and that researchers will conduct further analysis.
There were also animal bones inside the bucket, which is made of copper alloy and is decorated with a hunting scene. The National Trust said the bones were larger than those of a pig, and noted that horses were often included on funeral pyres as a symbol of status during this time. The bones will undergo radiocarbon dating, the National Trust said.
"We knew that this bucket would have been a rare and prized possession back in Anglo-Saxon times, but it's always been a mystery why it was buried," Wainwright said. "Now we know it was used to contain the remains of an important person in the Sutton Hoo community."
The bucket base, with bone fragments and the double-sided comb to the left.
FAS Heritage
The bucket was made in the Byzantine Empire and may have been a diplomatic gift or acquired by a mercenary Saxon soldier, the National Trust said. The vessel is decorated with a scene of men armed with swords and shields. The scene also includes lions and dogs. The newest fragments help complete the picture, showing feet, paws, the base of shields and the face of one hunting man.
Also inside the bucket was a double-sided comb that the National Trust said was likely made from antler. The agency said its researchers hope ancient DNA can be recovered from the object. The item was not burned in the cremation process, the National Trust noted. The inclusion of such combs in other burial sites suggest that "personal appearance and grooming was important to the Anglo-Saxons." The comb could also have been used to control lice, the trust said.
Plant remains were found during the excavation of the bucket pieces. Analysis of those pieces could "reveal more about the climate and seasonality around the time the bucket was buried," the National Trust said.
Time Team aired a documentary about the discovery and year-long analysis project earlier in May. The group will conduct more research at Sutton Hoo through mid-June.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Tezepelumab Curbs Oral Corticosteroid Use in Severe Asthma
The addition of tezepelumab to standard treatment allowed half the adults with severe asthma to discontinue their use of oral corticosteroids (OCS) after 1 year, according to new data from nearly 300 individuals. Tezepelumab, a human monoclonal antibody, has been associated with reduction in the use of OCS in patients with OCS-dependent asthma, David J. Jackson, MD, professor and clinical director, Guy's Severe Asthma Centre at Guy's Hospital King's College London, London, England, and colleagues wrote in an abstract presented at American Thoracic Society (ATS) 2025 International Conference. Many patients with severe asthma take OCS, but previous research has shown associations between extended OCS use and increased risk for a range of side effects including osteoporosis and fractures, hypertension, and infections, and more strategies are needed to help these patients reduce OCS use, the researchers noted. 'We know prolonged oral corticosteroid use leads to adverse effects, including bone, cardiovascular, metabolic, gastrointestinal and psychiatric disorders, and adrenal insufficiency,' Jackson said in an interview. 'The WAYFINDER trial is a multicenter, open-label, single-arm trial evaluating the efficacy and safety of tezepelumab compared to placebo in severe asthma patients who require maintenance use of OCS alongside their standard treatment,' he said. A previous phase 3 OCS-sparing study known as SOURCE did not meet its primary endpoint, but patients with baseline blood eosinophil counts ≥ 150 cels/μL who received tezepelumab achieved a reduction in daily maintenance OCS (mOCS) dose compared with placebo patients, the researchers wrote in their abstract. 'The WAYFINDER trial was designed to accelerate data collection and specifically address the complexities in the SOURCE trial design that may have contributed to the result of the primary endpoint,' Jackson told Medscape Medical News . The WAYFINDER trial enrolled 298 adults with severe asthma who had received OCS for at least 3 months before starting the study. All participants received 210 mg of subcutaneous tezepelumab every 4 weeks for up to 52 weeks after a 4-week induction period. The co-primary endpoints were the proportion of patients who reduced their daily mOCS to 5 mg/d or less or discontinued OCS without loss of asthma control. A total of 273 patients completed the study; the mean baseline mOCS was 10.8 mg/d, and patients were assessed at 28 weeks and 52 weeks. Overall, 88.9% and 89.9% of patients reduced their mOCS to 5 mg/d or less by week 28 and week 52, respectively, while 32.2% and 50.3% discontinued OCS at these time periods, respectively. In a post hoc analysis, 82.2% of patients whose reason for systemic corticosteroids was related to adrenal insufficiency achieved an mOCS dose of 5 mg/d or less without loss of asthma control at week 52. The study was limited by the open-label design, but the safety profile was consistent with previous studies of tezepelumab, researchers said. A 2023 meta-analysis of safety data on tezepelumab for uncontrolled asthma showed that the most common adverse events were nasopharyngitis, headache, and bronchitis, and most AEs occurred within a month of starting tezepelumab. Rates of serious adverse events were lower in patients receiving tezepelumab than those receiving placebo in a pooled analysis. The standout findings from the study are the clinically meaningful reductions in maintenance OCS use or complete discontinuation achieved with tezepelumab among a broad severe asthma patient population, Jackson told Medscape Medical News . In addition, two thirds of participants remained exacerbation-free despite OCS dose reductions, and the OCS-sparing effect of tezepelumab was observed across pre-specified patient subgroups, including those defined by baseline blood eosinophil counts (BEC), fractional exhaled nitric oxide (FeNO) level and allergy status, Jackson said. 'These findings reinforce tezepelumab's efficacy in severe asthma as the first and only biologic targeting thymic stromal lymphopoietin (TSLP) with demonstrated efficacy for severe asthma patients across phenotypes and irrespective of biomarker levels including BEC, allergic status, and FeNO,' he said. Improving Short-Term Health and Long-Term Wellness 'For people living with severe asthma, achieving stable control and reducing or eliminating reliance on oral corticosteroids is a critical goal, not only for respiratory health but also for long-term well-being,' Jackson told Medscape Medical News . 'By showing the benefit of targeting TSLP at the top of the inflammatory cascade and controlling asthma effectively with tezepelumab, we may be able to reduce these risks from OCS and significantly improve control for patients living with severe asthma,' Jackson said. 'We look forward to sharing a manuscript in the future for the phase 3b WAYFINDER study,' he added. Support for Steroid-Sparing The current study highlights an important population: Patients with asthma who are dependent on OCS, said Sucharita Kher, MD, pulmonologist and vice chair of clinical operations and quality for the Department of Medicine at Tufts Medical Center, in an interview. The endpoint tapering OCS without loss of asthma control is clinically meaningful because of the known side effects of OCS, said Kher, who was not involved in the study. The results were not unexpected, but more details on whether patients with eosinophils below 150 cells/µL also benefitted from tezepelumab would be helpful, Kher noted. The data are exciting because they suggest another option for patients with OCS dependent asthma, said Kher. 'The data also guide clinicians to adopt a strategy to wean patients off OCS when on tezepelumab with the goal of reducing OCS exposure and hence, side effects of prolonged OCS use,' she said. 'We know that OCS have side effects and negative consequences on factors including bone health, blood pressure, and blood sugar control and infection risk,' she added. Potential barriers to expanding the use of tezepelumab for reducing OCS in asthma patients exist at the patient and healthcare systems levels, Kher told Medscape Medical News . Patient-level barriers include cost sharing, worry/hesitancy about injections, lack of specialty access, and patient health literacy, she said. In addition, healthcare system barriers include a lack of knowledge on the part of primary care providers, and even some specialty physicians, of the benefits of biologics for severe asthma, said Kher. Other potential challenges include limited infrastructure in clinician offices, such as trained personnel and staff to navigate prior auth/insurance mandates, pre-authorization barriers, and denials based on tiers by insurance companies, she noted. 'Overcoming the barriers requires a multipronged approach, improving awareness and education for healthcare professionals, improve access to specialty care for patients, and advocacy to reduce the processes for insurance approvals,' Kher said.
Yahoo
an hour ago
- Yahoo
'Doctor Who' finale sees Ncuti Gatwa's 15th Doctor regenerate into a very familiar face, but what does it mean for the show?
When you buy through links on our articles, Future and its syndication partners may earn a commission. The Doctor is dead. Long live the Doctor! The era of Ncuti Gatwa's Fifteenth Doctor came to a surprise end on Saturday night, as the Time Lord regenerated at the end of "Doctor Who" season 2 finale "The Reality War". Massive spoilers ahead if you're yet to watch "The Reality War". You have been warned!!! With Time Lord supervillain Omega dispatched without hassle, both Ranis out of the picture, and reality on the way to being restored, the Doctor gradually realises that not everything is back to normal. Poppy, his daughter with Belinda Chandra in the "Wish World" fantasy, has been erased from history, so the Time Lord decides to sacrifice himself by firing a ton of regeneration energy into the time Vortex to "jolt it one degree" — and hopefully bring her back. It goes without saying that his madcap scheme saves Poppy, as we learn that, in this rewritten timeline, the little girl was always the reason Belinda had been desperate to get back home. But arguably the biggest talking point of the episode — and, indeed, the season — is saved until last, as the Doctor regenerates into a very familiar face… That's Billie Piper, the star of "Secret Diary of a Call Girl", "I Hate Suzie", "Mansfield Park" and the upcoming second season of "Wednesday". Much more relevant right now, however, is the fact she played the Doctor's companion, Rose Tyler, alongside Christopher Eccleston's Ninth Doctor and David Tennant's Tenth Doctor during the phenomenally successful first two seasons of the show's 2005 reboot. She's set to become the second female incarnation of the Time Lord after Jodie Whittaker's Thirteenth Doctor. Or the third if you count Jo Martin's Fugitive Doctor — though the explanation of how she fits into the Doctor's history is a little bit timey-wimey. After two seasons of adventuring through space and time with the Doctor, Rose was trapped in the parallel universe where the Cybus Industries had created the Cybermen. She was presumed dead back home. The Tenth Doctor subsequently used the power of a supernova to make final contact through a tiny gap in the universe, "burning up a sun just to say goodbye". During their emotional farewell, Rose told the Doctor, "I love you". "Quite right, too," he replied. "And I suppose. If it's my last chance to say it. Rose Tyler…" And then the message cut off, leaving his answer a mystery — though he definitely shed a Time Lord tear or two back on the TARDIS. That wasn't the end of Rose Tyler's story, however, because she managed to find a way back to her home universe to help the Doctor fight the Daleks in series 4 finale "The Stolen Earth"/"Journey's End". The fact she was the first of the new "Who" companions gives Rose a special place in many "Who" fans' hearts, and Piper's performance set an extremely high bar for every subsequent TARDIS sidekick. But there was always the sense that this was one Doctor/companion relationship where the affection ran both ways. The "Meta-Crisis Doctor" — a quasi-regeneration of the Tenth Doctor who was essentially human — even settled down with Rose in the aforementioned alternative universe. Rose has a particularly deep connection to the TARDIS, having looked directly into its Time Vortex in series 1 finale "Bad Wolf"/"The Parting of the Ways". This briefly transformed her into the omnipotent Bad Wolf entity, but — despite effectively becoming a god — she'd absorbed too much energy for a human body to handle. The Ninth Doctor saved Rose by absorbing the Vortex energy into himself, triggering his regeneration into the Tenth Doctor. It was also no coincidence that Rose Noble (Yasmin Finney), daughter of later Tenth Doctor companion Donna, chose Tyler's name for herself after she came out as transgender — although all of Donna's recollections of her time in the TARDIS had been wiped, some residual memories had been passed down to her daughter. That's the big mystery, though it's not the first time the Doctor has regenerated into a familiar body. Most famously, David Tennant returned to play a Fourteenth Doctor who was the spitting image of the Tenth Doctor. Meanwhile, Sixth Doctor Colin Baker had previously played Commander Maxil in Fifth Doctor story "Arc of Infinity", and Twelfth Doctor Peter Capaldi had portrayed Caecilius in Tenth Doctor story "The Fires of Pompeii". (Capaldi also appeared in "Who" spin-off "Torchwood", though the Doctor was elsewhere during the events of "Children of Earth".) "Billie once changed the whole of television, back in 2005, and now she's done it again!" showrunner Russell T Davies teased after the big Billie Piper reveal. "It's an honour and a hoot to welcome her back to the TARDIS, but quite how and why and who is a story yet to be told. After 62 years, the Doctor's adventures are only just beginning!" Another excellent question, and it would be unwise to make any assumptions — in fact, even "The Reality War"'s end titles have been engineered to add to the mystery. Although the show's post-regeneration credits have traditionally featured the line "And introducing [insert name] as the Doctor", here it simply says "And introducing Billie Piper". The omission of "as the Doctor" is unlikely to be accidental, suggesting that Davies is playing a very elaborate game with "Who" fandom. (It's also worth noting that Piper played a personification of an ancient Gallifreyan weapon of mass destruction called the Moment in the 50th anniversary special "The Day of the Doctor". In other words, there's a precedent for the star playing new and unexpected roles in "Doctor Who".) Another mystery! The BBC and Disney+ are yet to confirm if and when "Doctor Who" will return for a third season of its current iteration. Davies told Radio Times back in April that, "There's no decision until after season 2," so the powers-that-be are presumably waiting to see the latest episodes' viewing figures before making a call. Hopefully, they'll be influenced by the fact that we still don't know why the Doctor's granddaughter, Susan, has been calling out to him. It's one hell of a loose end… In the meantime, it feels appropriate to leave the final word (for now) to the Doctor-elect: "I love this show, and I have always said I would love to return to the Whoniverse as I have some of my best memories there," said Piper. "So to be given the opportunity to step back on that TARDIS one more time was just something I couldn't refuse. But who, how, why and when, you'll just have to wait and see." Every episode of "Doctor Who" season 2 is now available to stream on BBC iPlayer in the UK and Disney+ in the US. All of Billie Piper's previous adventures in the TARDIS are currently available on BBC iPlayer in the UK.
Yahoo
3 hours ago
- Yahoo
College students design workshops for special needs school kids
North East college students are bringing hands-on STEM learning to life through interactive workshops. A new partnership between Middlesbrough College and Discovery Special Academy in Middlesbrough is helping young people with complex learning needs explore science and technology through creative, student-led sessions. The project began when Discovery Special Academy sought support to strengthen its STEM and careers provision, leading to a recommendation from video game developer Double Eleven and a collaboration with Middlesbrough College's Digital department. Cher Griffiths, curriculum team leader at Middlesbrough College, said: "The experience has been incredibly rewarding for our students, who have stepped outside their comfort zones and learned how to engage meaningfully with children who have special educational needs. "The feedback from both sides has been fantastic. "Watching the students work together to achieve something meaningful has been inspiring – it's what our social action projects are all about." Over the past three months, college students have designed and led practical workshops in robotics, problem-solving, photography, and more. Pupils have built cars and robots using Lego Mindstorms, taken part in digital photography activities, and created visual storytelling projects. One session involved using puppets to tell the story of a typical day at the academy. College students helped the children set up scenes, take photographs, and assemble a visual narrative. The collaboration has also led to the creation of a bank of classroom resources for Discovery Special Academy's teaching staff to use beyond the life of the project. The partnership will continue for the remainder of the academic year, with plans for academy pupils to visit Middlesbrough College and explore its digital facilities, including a professional film studio and e-sports arena. Both organisations say the project has delivered meaningful benefits for all involved. Pupils have gained new experiences in STEM, while college students have developed skills in leadership, communication, and creative problem-solving. Middlesbrough College hopes to expand the partnership in the future, exploring new areas of digital learning and building on the success of this year's social action project.
